A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Three Months Administration of SB-683699 (150 - 1200mg Twice Daily) in Subjects With Relapsing Multiple Sclerosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2015

At a glance

  • Drugs Firategrast (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Oct 2008 Actual start date changed from Aug 2004 to Sep 2004 as reported by Clinicaltrials.gov.
    • 14 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 09 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top